XORTX Therapeutics (XRTX) Q4 2025 earnings summary

Executive summary

• Focused on late-stage clinical development of therapies for gout, autosomal dominant polycystic kidney disease (ADPKD), diabetic nephropathy, and acute kidney injury (AKI) associated with respiratory virus infection.

• Lead program XRx-026 targets allopurinol-intolerant gout patients, with NDA submission planned within 12 months, aiming for a US$700M/year market.

• Pipeline includes XRx-008 (ADPKD, orphan drug designation), XRx-101 (AKI in respiratory virus infection), and XRx-225 (diabetic nephropathy).

• Recent acquisition of Vectus Biosystems' renal anti-fibrotic program expands pipeline.

Financial highlights

• Net loss for 2025: US$2.66M, improved from US$3.31M in 2024 and US$2.16M in 2023.

• Accumulated deficit as of Dec 31, 2025: US$23.82M.

• Cash and cash equivalents at year-end 2025: US$0.86M (down from US$2.47M in 2024).

• Shareholders’ equity at year-end 2025: US$2.08M.

• No revenue generated; company remains pre-commercial.

Outlook and guidance

• Plans to file NDA for XRx-026 (gout) within 12 months, targeting accelerated approval for XRx-008 (ADPKD).

• Ongoing efforts to secure additional funding for clinical development and commercialization.

• Strategic focus on expanding pipeline through acquisitions and in-licensing.